CHANGCHUN, China and LOS ANGELES, Jan. 25 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals,Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or the "Company"), is a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical
In pursuit of the Company's new sales strategy, China Yongxin Pharmaceuticals plans to open twenty eight new retail stores in 2010 to expand its customer base and increase market share. Among them, ten stores will be located in Tianjin City with an average operating area of 160 square meters per store and a local customer population of 20,000. The Company plans to open stores at the rate of two per month from March through November 2010. These stores, considered together, are projected to achieve an average annualized revenue of $466,181.
Eight new stores will be opened in Changchun City, from March to September 2010, each with an operating area of 142.5 square meters. These new stores offer products and services to a local customer population of 15,000 each, and these stores, considered together, are expected to achieve an average annualized revenue of $371,720.
Ten new stores will be opened in Baishan City with an average operating area of 80 square meters per store. Reaching out to an average customer population of 5,000, these stores, considered together, are expected to bring an average annualized revenue stream of $193,586 to the Company.
If successfully opened, the 28 new stores together with the Company's existing stores will make Yongxin one of the top 3 drug retailers in the Jilin Province pharmaceutical retail market in terms of store presence. Already ranked as the No. 1 pharmaceutical distributor in the Jilin Province by capacity, the Company's market share is expected to substantially increase in the Northeast China area.
Already benefiting from an expanded product portfolio including 98% of the items listed on the recently issued Essential Drug List (EDL) in China and its increased marketing campaign activities, Yongxin believes these new stores will continue to contribute to revenue in the Company's retail drug operations in 2010 and beyond. In the year 2009, retail drug revenue increased by approximately 30% over the year 2008, along with an increase in gross profit of 28%.
If the Company manages to boost market share in the Jilin Province, Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin, commented, "government support for our company will be further enhanced, especially following the implementation of China's $126 billion health care reform plan that focuses on providing a broader spectrum of healthcare services and pharmaceutical products to all Chinese residents. We are confident that our modernized logistics center and distribution channels, the significantly broader customer base of our chain drugstores, our extensive product portfolio, and committed management team, bode well for the long term growth of our company."
About China Yongxin Pharmaceuticals, Inc.
China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), is a manufacturer, retailer and distributor of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in Northeastern China. Its retail operations began in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing drug retailers in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.
For more information, please contact: For the Company: Mr. Sam Liu, COO China Yongxin Pharmaceuticals, Inc. Tel: +1-626-581-9098 Email: [email protected] Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: [email protected] Web: http://www.hcinternational.net
SOURCE China Yongxin Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All